Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Atezolizumab Monotherapy Falls Short in Exploratory OS Analysis in Untreated Locally Advanced or Metastatic Urothelial Cancer

February 18th 2023

Atezolizumab monotherapy failed to show an improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Dr. Galsky on Updated Findings From the CheckMate-274 Trial in Urothelial Cancer

February 17th 2023

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Dr. Berg on Key Ongoing Trials in Metastatic Urothelial Carcinoma

February 14th 2023

Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.

Dr. Singh on the Continued Investigation of Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

February 13th 2023

Vikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

Dr. Singh on Treatment Updates in Urothelial Carcinoma

February 10th 2023

Vikas Kumar Singh, MD, discusses findings from the phase 3 GETUG-AFU V05 VESPER (NCT01812369) and JAVELIN Bladder 100 (NCT02603432) trials in patients with bladder cancer.

Dr. Berg the Promise of Key Updates in Urothelial Cancer

February 7th 2023

Stephanie A. Berg, DO, discusses the promise of key updates in urothelial cancer, as well as highlights how these updates continue to affect treatment decisions for patients.

RaDaR Assay Predicts Patient Response to Immunotherapy in Stage III Bladder Cancer

February 6th 2023

The RaDaR assay successfully identified the patients with locoregionally advanced urothelial cancer most likely to benefit from treatment with ipilimumab and nivolumab in findings from the second cohort of the phase 1b/2a NABUCCO trial.

Dr. Grivas on Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma

February 6th 2023

Petros Grivas, MD, PhD, discusses the investigation of enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma.

Immunotherapy Propels Urothelial Carcinoma Treatment Advances

February 2nd 2023

Stephanie A. Berg, DO, highlights ongoing urothelial cancer clinical trials; the role of single-agent immunotherapy and combinations in this disease; and the importance of future research that prioritizes and guides individualized patient care.

IK-175 Monotherapy or Plus Nivolumab Shows Early Activity in Urothelial Cancer

January 22nd 2023

IK-175 was found to be well tolerated in patients with advanced solid tumors and to elicit responses in those with urothelial cancer when used alone or in combination with nivolumab, according to initial data from an ongoing phase 1a/b study.

Dr. Zhang on the EV-302 Trial in Metastatic Urothelial Cancer

January 16th 2023

Tian Zhang, MD, discusses the investigation of the combination of enfortumab vedotin plus pembrolizumab in the phase 3 EV-302 trial in the frontline setting for metastatic urothelial cancer.

Dr. Aragon-Ching on the Use of Maintenance Avelumab in Urothelial Carcinoma

January 6th 2023

Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma.

FDA Grants Fast Track Status to BT8009 for Previously Treated Locally Advanced or Metastatic Urothelial Cancer

January 5th 2023

The FDA has granted a fast track designation to BT8009 for use as a monotherapy in adult patients with previously treated locally advanced or metastatic urothelial cancer.

Trilaciclib Plus Chemotherapy and Avelumab Maintenance Generates Comparable ORR in Advanced/Metastatic Urothelial Carcinoma

January 5th 2023

Adding the CDK4/6 inhibitor trilaciclib to platinum-based chemotherapy and avelumab maintenance produced an overall response rate comparable to chemotherapy and maintenance avelumab alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

N-803 Plus BCG Generates Strong, Durable Response in Non–Muscle Invasive Bladder Cancer

January 4th 2023

N-803, a novel IL-15 superagonist, in combination with intravesical Bacillus Calmette–Guérin induced an overall response in more than two-thirds of patients with non–muscle invasive bladder cancer.

FDA Accepts sBLAs for Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

December 20th 2022

The FDA has granted a priority review to a supplemental biologics license applications for enfortumab vedotin and pembrolizumab used in combination for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

FDA Approves Nadofaragene Firadenovec for High-risk Non–Muscle Invasive Bladder Cancer

December 16th 2022

The FDA has approved nadofaragene firadenovec-vncg (Adstiladrin) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across Locally Advanced or Metastatic Solid Tumors

December 6th 2022

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

December 1st 2022

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

CG0070/Pembrolizumab Combo Shows Promising Efficacy and Tolerability in NMIBC

November 30th 2022

The oncolytic vaccine CG0070 plus pembrolizumab demonstrated encouraging response rates and a tolerable safety profile in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.